bioAffinity Technologies, Inc. (BIAF) vs iSpecimen Inc. (ISPC)
A side-by-side comparison of bioAffinity Technologies, Inc. and iSpecimen Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BIAF
bioAffinity Technologies, Inc.
$6.01HealthcareDelayed quote: Oct 6, 2026, 10:40 AM EDT
ISPC
iSpecimen Inc.
$1.05HealthcareDelayed quote: Oct 6, 2026, 10:39 AM EDT
Total return — BIAF vs ISPC
growth of $100 · dividends reinvested · last 4yBIAF -99.8% (-79.8%/yr)ISPC -99.9% (-84.4%/yr)BIAF compounded faster over this window
BIAF ISPC
BIAF vs ISPC: by the numbers
- •ISPC is the larger company ($3M vs $3M market cap).
- •Both run net losses; BIAF's is the smaller (-257.33% vs -2449.04% net margin).
Metrics side by side
Valuation
| Metric | BIAF | ISPC |
|---|---|---|
| P/S ratio | 0.43 | 5.64 |
| P/B ratio | 0.67 | 1.52 |
Profitability
| Metric | BIAF | ISPC |
|---|---|---|
| Gross margin | 23.21% | 1.25% |
| Operating margin | -171.58% | -465.42% |
| Net margin | -257.33% | -2449.04% |
| ROE | -402.92% | -657.69% |
| ROIC | -237.93% | -476.39% |
Growth (annualized)
| Metric | BIAF | ISPC |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -46.70% |
| Total return CAGR (5Y) | N/A | -81.14% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.